Detection of copy loss or copy‐neutral loss of heterozygosity (cnLOH) of the TP53 gene, along with mutations, is especially critical in patients with MDS, as only biallelic TP53 inactivations (MDS‐biTP53) are associated with an inferior outcome and recognized as a distnict disease entity in WHO/ICC classifications. This evidence concerns the gene TP53 and myelodysplastic syndrome.